Outlook Therapeutics, Inc. (OTLK)
Develops eye drop antibody treatments for vision diseases like macular degeneration
$0.90-0.15%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-53.2%
The outlook
Outlook Therapeutics trades near $0.90, well below both its 50- and 200-day averages and sitting toward the lower end of its 52-week range. Analyst consensus is strongly bullish with an average price target implying roughly 497% upside from current levels, though coverage is limited to four analysts. The overall score reflects a neutral lean despite the bullish analyst view, suggesting caution about the divergence between sentiment and recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +497% vs current price
Analyst price target
~12-month · 4 analysts$5.40average target+497.3% vs now
Now $0.90
Low $1.60High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$169.0M
52-wk high
$3.39
52-wk low
$0.16
50-day avg
$1.14
200-day avg
$0.94
Trailing P/E
—